# Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

> **NCT07168434** · PHASE3 · RECRUITING · sponsor: **Biocodex** · enrollment: 406 (estimated)

## Conditions studied

- IBS (Irritable Bowel Syndrome)
- IBS-D (Diarrhea-predominant)
- IBS, Mixed Symptoms

## Interventions

- **DRUG:** Saccharomyces Boulardii 250 MG
- **DRUG:** Placebo 250 mg

## Key facts

- **NCT ID:** NCT07168434
- **Lead sponsor:** Biocodex
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-22
- **Primary completion:** 2026-10-11
- **Final completion:** 2026-10-11
- **Target enrollment:** 406 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07168434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07168434, "Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07168434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*